Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BW723C86 is a tryptamine derivative and small molecule that functions primarily as a serotonin 5-HT2B receptor agonist, with additional activity at the 5-HT2C receptor and minimal activity at the 5-HT2A receptor. In animal studies, it shows anxiolytic effects and is used principally as a research tool to study serotonin receptor function, especially 5-HT2B-mediated responses. It does not induce psychedelic-like behaviors associated with 5-HT2A agonism. In vitro studies have shown that BW723C86 induces skin whitening in human melanocytes by reducing expression of MITF and key melanogenic enzymes (tyrosinase, TRP-1, and TRP-2) without being cytotoxic or inhibiting tyrosinase activity directly. The drug is not approved for clinical use and is sold for research purposes only[1][2][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BW723C86.